We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs.

Biogen has turned to M&A to offset its ... getting a green light from the FDA in February. The drug has started to roll out with a list price of $370,000 a year, which Jefferies analysts think ...

Leqembi, which Biogen shares with the Japanese drugmaker Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. in 2023. The therapy's launch has ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the ...

Biogen nonetheless restarted the Federal Drug Administration approval process in 2019 ... In fact, Medicare often pays more than the list price in the short term: For most Part B drugs, it reimburses ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...